Definium Therapeutics, Inc.

What they do

Definium develops product candidates targeting neurotransmitter pathways involved in brain health disorders, specifically optimized compounds from the psychedelic and empathogen drug classes. Its lead candidate, DT120 ODT, is a proprietary form of lysergide D-tartrate being developed for generalized anxiety disorder (GAD) and major depressive disorder (MDD). A second lead candidate, DT402 (R(-)-MDMA), is also in development. The company commenced operations in 2019, has not generated any revenue, and has no products approved for commercial sale.

Revenue drivers

• DT120 ODT for GAD — Most advanced program; Phase 3 Voyage and Panorama trials completed enrollment in 2026, with topline data anticipated in August and September 2026. No revenue to date; commercial potential depends on future approval.
• DT120 ODT for MDD — Phase 3 Emerge study reported positive topline results in the August 2026 earnings release; the Ascend trial initiated enrollment with topline expected in 2027. No revenue to date.
• DT120 ODT for PTSD — Phase 3 Haven study is expected to initiate in 2027 with approximately 200 participants. No revenue to date; earliest-stage of the disclosed DT120 indications.
• DT402 (R(-)-MDMA) — Described as a lead product candidate derived from the empathogen class, but the provided excerpts give no trial stage, timeline, or size detail. No revenue to date.

Recent performance

For the quarter ended June 30, 2026, Definium reported cash, cash equivalents and investments of approximately $1.1 billion, up from $411.6 million as of December 31, 2025, primarily reflecting an underwritten public offering of 23,676,471 common shares for gross proceeds of $805 million and net proceeds of approximately $757.9 million. The company reported positive topline results from the Phase 3 Emerge study of DT120 ODT in MDD, with a placebo-adjusted improvement of 8.1 MADRS points at Week 6 (Cohen's d = 0.83; p<0.0001) and 7.3 points at Week 12 (p<0.0001). Annual net loss widened to $183.8 million in 2025 from $108.7 million in 2024, and operating cash flow declined to negative $131.6 million in 2025 from negative $79.1 million in 2024. Definium has no approved products and has generated no revenue.

Strategy

Definium's stated mission is to apply scientific rigor to psychedelics and develop accessible treatments for brain health disorders at scale. The company is funding a broad Phase 3 program across GAD, MDD and PTSD using the approximately $1.1 billion in cash, cash equivalents and investments reported at June 30, 2026. It completed enrollment in the GAD Voyage and Panorama studies and initiated enrollment in the MDD Ascend study during 2026, and expects to start the PTSD Haven study in 2027. Management also launched Wired for Worry, a healthcare provider disease education platform for GAD, indicating early commercial-preparation activity. The company states it believes its cash position is sufficient to fund operations based on its current operating plan and anticipated milestones, though the provided excerpt does not quantify the runway.

Risks

• No approved products or revenue — Definium has no products approved for commercial sale and has not generated any revenue, so its viability depends entirely on the success of investigational candidates.
• Dependence on DT120 — The company's own risk factors state reliance on the success of the investigational DT120 product candidate, which is the basis for the GAD, MDD and PTSD programs.
• Pivotal trial execution risk — Definium has not completed any pivotal clinical trials, and its Phase 3 readouts (Voyage, Panorama, Ascend, Haven) remain subject to timing and outcome uncertainty.
• Cash burn and financing need — Net loss widened to $183.8 million in 2025 and operating cash flow was negative $131.6 million, requiring continued capital to fund the Phase 3 programs.

Outlook

Management said the second quarter of 2026 was a meaningful inflection point, citing the positive Phase 3 Emerge results in MDD and the approximately $805 million gross public offering proceeds. Topline data from the Phase 3 GAD Voyage study were anticipated the week of August 10, 2026, and Panorama results are anticipated in September 2026. The Phase 3 MDD Ascend study's topline data are expected in 2027, and the PTSD Haven study is expected to initiate in 2027. The company states it believes its June 30, 2026 cash, cash equivalents and investments are sufficient to fund operations under its current operating plan and anticipated milestones.